Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer licenses TransTech drugs

September 25, 2006 | A version of this story appeared in Volume 84, Issue 39

Pfizer has signed a licensing agreement with TransTech Pharma for small- and large-molecule compounds under development by TransTech for the treatment of Alzheimer's disease. The compounds target the receptor for advancing glycation end products (RAGE). The most advanced are TTP488, an orally available small-molecule candidate that is in Phase II clinical trials, and TTP4000, a large molecule expected to begin Phase I trials this year. Under the agreement, Pfizer gains exclusive rights to TransTech's RAGE modulator portfolio. TransTech will receive up-front and near-term milestone payments totaling $155 million and could earn additional unspecified milestone and royalty payments.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.